Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer
Authors
Keywords
Renal cell carcinoma, Prostate cancer, Programmed death 1
Journal
Current Oncology Reports
Volume 15, Issue 2, Pages 98-104
Publisher
Springer Nature
Online
2012-12-21
DOI
10.1007/s11912-012-0284-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
- (2011) M. Terme et al. CANCER RESEARCH
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
- (2011) A. M. Paterson et al. JOURNAL OF IMMUNOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
- (2010) M. Kujawski et al. CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Enhancing SIV-specific immunity in vivo by PD-1 blockade
- (2008) Vijayakumar Velu et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now